Shares of Johnson & Johnson (NYSE: JNJ) gained in pre-market trading on Tuesday after the company reported Q4 earnings of $2.35 per share, up 10.3% year-over-year which beat analysts’ consensus estimate of $2.23 per share.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
However, the company that develops medical devices, pharmaceuticals, and consumer packaged goods saw sales decline by 4.4% year-over-year, with revenue hitting $23.7 billion. This beat analysts’ expectations by $200 million.
Looking forward, management now expects revenue and adjusted earnings per share for FY23 to be in the ranges of $96.9 billion to $97.9 billion and between $10.45 and $10.65, respectively. For reference, analysts are expecting $97.73 billion in revenues along with an adjusted EPS of 10.33.
Overall, Wall Street analysts are cautiously optimistic about the stock with a Moderate Buy consensus rating based on three Buys and three Holds. Johnson & Johnson has a consensus price target of $189.50 on JNJ stock, implying a 12.6% upside potential, as indicated by the graphic above.
Join our Webinar to learn how TipRanks promotes Wall Street transparency